Fibrates for primary prevention of cardiovascular disease events-Reference-Cited by-同舟云学术

Fibrates for primary prevention of cardiovascular disease events

Published:2016-11-16 Issue:3 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Jakob Tobias¹,Nordmann Alain J¹,Schandelmaier Stefan¹,Ferreira-González Ignacio²,Briel Matthias¹

Affiliation:

1. University of Basel; Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research; Basel Switzerland

2. Vall d'Hebron Hospital; Cardiology Department, Epidemiology Unit; Passeig Vall d'Hebron 119-129 Barcelona Barcelona Spain 08035

Publisher

Wiley

Subject

Pharmacology (medical)

Reference115 articles.

1. Effects of combination lipid therapy in type 2 diabetes mellitus;Friedewald;New England Journal of Medicine,2010

2. Effects of medical therapies on retinopathy progression in type 2 diabetes;Friedewald;New England Journal of Medicine,2010

3. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial;Williamson;JAMA,2014

4. Efficacy and safety of etofibrate in patiens with non-proliferative diabetic retinopathy;Emmerich;Klinisches Monatsblatt der Augenheilkunde,2009

5. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study;D'Emden;Diabetologia,2014

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triglyceride/High Density Lipoprotein Cholesterol Index and Future Cardiovascular Events in Diabetic Patients without Known Cardiovascular Disease;2024-09-01

2. Associations of metabolic disorders with hypertension and cardiovascular disease: recent findings and therapeutic perspectives;Hypertension Research;2024-05-29

3. JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease;Circulation Journal;2024-04-25

4. Lipid-lowering therapies in patients undergoing percutaneous coronary intervention;Vessel Plus;2024-04-08

5. Lipid-lowering therapies in patients undergoing percutaneous coronary intervention;Vessel Plus;2024-04-08